Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2021, with a specific reporting date of July 15, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data present relates to specific share transactions:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $40.4435 per ADS.
- Transaction Date: July 13, 2021.
- Exchange: New York Stock Exchange (XNYS).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses the acquisition of ADSs by four executives following the re-investment of dividends paid to shareholders on July 8, 2021.
Management Commentary and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of routine dividend reinvestment transactions.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ADSs via dividend reinvestment, not open market purchases or sales.
- Executives Involved:
- Dr. H. Barron (Chief Scientific Officer and President, R&D): Acquired 1,225.247 ADSs.
- Mr. J. Ford (SVP & General Counsel): Acquired 120.105 ADSs.
- Mr. B. McNamara (CEO, GSK Consumer Healthcare): Acquired 1,703.274 ADSs.
- Ms. K. Terrell (Chief Digital & Technology Officer): Acquired 571.067 ADSs.
- Dividend Context: The transactions were triggered by dividends paid on July 8, 2021.
- Financial Data Limitation: This filing does not contain quarterly or annual financial performance data; investors should refer to Form 20-F or quarterly reports for those metrics.